Premixed i.v. admixtures for reducing costs and labor time in a home infusion company

被引：2
|
作者：
Petroff, BJ [1 ]
机构：
[1] Apria Healthcare, Ann Arbor, MI 48108 USA
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2000年 / 57卷 / 04期
关键词：
D O I：
10.1093/ajhp/57.4.390
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：390 / 390
页数：1
相关论文
共 50 条
  • [31] INFLUENCE OF THE STRUCTURE OF NEW ANTHRACYCLINE ANTIBIOTICS IN THEIR STABILITY IN COMMONLY USED I.V. INFUSION SOLUTIONS
    Cielecka-Piontek, Judyta
    Jelinska, Anna
    Dolhan, Agnieszka
    Oszczapowicz, Irena
    Wasowska, Malgorzata
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3242 - 3242
  • [32] A mathematical model describing the glycemic response of diabetic patients to meal and i.v. infusion of insulin
    Fabietti, PG
    Calabrese, G
    Iorio, M
    Bistoni, S
    Brunetti, P
    Sarti, E
    Benedetti, MM
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2001, 24 (10): : 736 - 742
  • [33] Glycine toxicity after high-dose i.v. infusion of 1.5% glycine in the mouse
    Olsson, J
    Hahn, RG
    BRITISH JOURNAL OF ANAESTHESIA, 1999, 82 (02) : 250 - 254
  • [34] Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime
    Hitt, CM
    Nightingale, CH
    Quintiliani, R
    Nicolau, DP
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (14) : 1614 - 1618
  • [35] Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis
    Yamamoto, Tomonori
    Yamamura, Hitoshi
    Yamamoto, Hiromasa
    Mizobata, Yasumitsu
    ACUTE MEDICINE & SURGERY, 2016, 3 (03): : 237 - 243
  • [36] Phase I dose finding study of irinotecan (CPT-11) over a short i.v. infusion combined with a fixed dose of 5-fluorouracil (5-FU) protracted continuous i.v. infusion in patients with advanced solid tumours
    Sastre, J
    PazAres, L
    DiazRubio, E
    CortesFunes, H
    Carcas, A
    Gruia, G
    Herait, P
    FdzChacon, C
    Martin, C
    Farr, I
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1141 - 1141
  • [37] Safety and efficacy of coagulation Factor VIIa (recombinant) when administered as i.v. bolus or i.v. continuous infusion to hemophilia A or B patients with inhibitors undergoing elective major surgical procedures
    Gilchrist, GS
    Green, D
    Hoots, K
    Konkle, BA
    Erhardtsen, E
    THROMBOSIS AND HAEMOSTASIS, 1999, : 97 - 98
  • [38] A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours
    Sastre, J
    Paz-Ares, L
    Carcas, A
    Alfonso, R
    Grávalos, C
    Frias, J
    Guerra, P
    Pronk, L
    Cortes-Funes, H
    Diaz-Rubio, E
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (05) : 453 - 460
  • [39] A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours
    Javier Sastre
    Luis Paz-Ares
    Antonio Carcas
    Rosario Alfonso
    Cristina Grávalos
    Jesus Frías
    Pedro Guerra
    Linda Pronk
    Hernán Cortés-Funes
    Eduardo Díaz-Rubio
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 453 - 460
  • [40] TOLERANCE OF I.V. IMMUNOGLOBULIN INFUSIONS GIVEN AT INCREASED INFUSION RATE RELATED TO BODY WEIGHT 57
    A Fasth
    A M Olinder-Nielsen
    S Oskarsdóttir
    V A Oxelius
    A Vietorisz
    Pediatric Research, 1997, 41 (5) : 753 - 753
12345